Litcius/Paper detail

Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients

Evangelia Pantazaka, Vasileios Vardas, Argyro Roumeliotou, Stavros Kakavogiannis, Galatea Kallergi

2021Cancers36 citationsDOIOpen Access PDF

Abstract

Lung cancer is the leading cause of cancer-related mortality globally. Among the types of lung cancer, non-small-cell lung cancer (NSCLC) is more common, while small-cell lung cancer (SCLC) is less frequent yet more aggressive. Circulating tumor cells (CTCs), albeit rare, have been portrayed as essential players in the progression of lung cancer. CTCs are considered to adopt an epithelial-to-mesenchymal transition (EMT) phenotype and characteristics of cancer stem cells (CSCs). This EMT (or partial) phenotype affords these cells the ability to escape from the primary tumor, travel into the bloodstream, and survive extremely adverse conditions, before colonizing distant foci. Acquisition of CSC features, such as self-renewal, differentiation, and migratory potential, further reflect CTCs' invasive potential. CSCs have been identified in lung cancer, and expression of EMT markers has previously been correlated with poor clinical outcomes. Thus far, a vast majority of studies have concentrated on CTC detection and enumeration as a prognostic tools of patients' survival or for monitoring treatment efficacy. In this review, we highlight EMT and CSC markers in CTCs and focus on the clinical significance of these phenotypes in the progression of both non-small- and small-cell lung cancer.

Topics & Concepts

Lung cancerCirculating tumor cellCancer stem cellCancerPhenotypeEpithelial–mesenchymal transitionMedicineClinical significanceMesenchymal stem cellCancer researchPathologyOncologyBiologyInternal medicineMetastasisBiochemistryGeneCancer Cells and MetastasisMetastasis and carcinoma case studiesCancer Genomics and Diagnostics
Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients | Litcius